Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sensitization

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    147 result(s) found for: Sensitization. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2005-001622-91 Sponsor Protocol Number: RKMMS 04 Start Date*: 2005-06-23
    Sponsor Name:Royal Group Hospitals
    Full Title: A randomised assessor blinded study to examine the role of skin testing in the prediction of peri-operative anaphylaxis and its correlation with mast cell tryptase and total IgE.
    Medical condition: Prevalance of sensitivity of immune system to the four named neuromuscular blocking drugs in patients undergoing anaesthesia.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-005404-29 Sponsor Protocol Number: E2I60 Start Date*: 2015-12-04
    Sponsor Name:SANOFI PASTEUR SA
    Full Title: Safety of the DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM®) Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China
    Medical condition: Healthy volunteers: active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive infections caused by Haemophilus influenzae type b (such as meningitis, septicaemia, cellu...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10042613 - Surgical and medical procedures 10036897 Prophylactic vaccination LLT
    18.1 10042613 - Surgical and medical procedures 10043413 Therapeutic procedures and supportive care NEC HLGT
    18.1 10042613 - Surgical and medical procedures 10021430 Immunisation PT
    18.1 10042613 - Surgical and medical procedures 10021431 Immunisations HLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-000473-25 Sponsor Protocol Number: ESKEFIB Start Date*: 2020-06-30
    Sponsor Name:Grand Hôpital de Charleroi
    Full Title: ESKETamine for FIBromyalgia treatment
    Medical condition: Patients diagnosed with a fibromyalgia syndrome as established by the 2016 ACR criteria and presenting criteria of central sensitization syndrome (based of the CSI (CSI>40)).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001087-28 Sponsor Protocol Number: RC31/19/0511 Start Date*: 2020-12-29
    Sponsor Name:CHU Toulouse
    Full Title: Anti-IL6 receptor antibodies to reduce allo-sensitization post allograft nephrectomy ; a pilot phase II study
    Medical condition: kidney transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10029116 Nephrectomy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004450-26 Sponsor Protocol Number: A3L26 Start Date*: 2012-04-10
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Phase III, multi-center study in children fully vaccinated with a three-dose primary and the booster dose of the DTaP-IPV-Hep B-PRP-T combined vaccine or CombAct-Hib™ and OPV and Engerix™ B in Stud...
    Medical condition: Prevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus type 1, 2 and 3, prevention against invasive infections caused by Haemophilus in...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10021430 Immunisation PT
    14.1 10042613 - Surgical and medical procedures 10036897 Prophylactic vaccination LLT
    14.1 10042613 - Surgical and medical procedures 10021431 Immunisations HLT
    14.1 10042613 - Surgical and medical procedures 10043413 Therapeutic procedures and supportive care NEC HLGT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-005293-38 Sponsor Protocol Number: E2I49 Start Date*: 2015-12-04
    Sponsor Name:SANOFI PASTEUR SA
    Full Title: Immunogenicity and Safety of the sanofi pasteur’s DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM™) versus sanofi pasteur’s DTacP-IPV Combined Vaccine (TETRAXIM™) given simultaneously at separate sites...
    Medical condition: Healthy volunteers: active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive infections caused by Haemophilus influenzae type b (such as meningitis, septicaemia, cellu...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10042613 - Surgical and medical procedures 10036897 Prophylactic vaccination LLT
    18.1 10042613 - Surgical and medical procedures 10043413 Therapeutic procedures and supportive care NEC HLGT
    18.1 10042613 - Surgical and medical procedures 10021430 Immunisation PT
    18.1 10042613 - Surgical and medical procedures 10021431 Immunisations HLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-005403-87 Sponsor Protocol Number: E2I57 Start Date*: 2015-12-04
    Sponsor Name:SANOFI PASTEUR SA
    Full Title: Immunogenicity and Safety of the sanofi pasteur’s DTacP-IPV Combined Vaccine (TETRAXIM™) given as a booster dose at 4 to 6 years of life in children previously vaccinated with PENTAXIM™ in the stud...
    Medical condition: Healthy volunteers: indicated for primary vaccination in infants for active immunization against diphtheria, tetanus, pertussis and poliomyelitis.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10042613 - Surgical and medical procedures 10036897 Prophylactic vaccination LLT
    18.1 10042613 - Surgical and medical procedures 10043413 Therapeutic procedures and supportive care NEC HLGT
    18.1 10042613 - Surgical and medical procedures 10021430 Immunisation PT
    18.1 10042613 - Surgical and medical procedures 10021431 Immunisations HLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-005348-33 Sponsor Protocol Number: E2I28 Start Date*: 2015-12-04
    Sponsor Name:SANOFI PASTEUR LTD
    Full Title: Immunogenicity and safety of Sanofi Pasteur’s DTaP-IPV combined vaccine (TETRAXIM™) given as a three-dose primary vaccination in South Korean healthy infants, as compared to commercially available ...
    Medical condition: Healthy volunteers: indicated for primary vaccination in infants for active immunization against diphtheria, tetanus, pertussis and poliomyelitis.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10042613 - Surgical and medical procedures 10036897 Prophylactic vaccination LLT
    18.1 10042613 - Surgical and medical procedures 10043413 Therapeutic procedures and supportive care NEC HLGT
    18.1 10042613 - Surgical and medical procedures 10021430 Immunisation PT
    18.1 10042613 - Surgical and medical procedures 10021431 Immunisations HLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-003267-55 Sponsor Protocol Number: A3L45 Start Date*: 2015-09-03
    Sponsor Name:Sanofi Pasteur SA
    Full Title: An international, multicenter, open-label, one-arm study in 150 infants vaccinated with a 3-dose primary series of the DTaP-IPV-Hep B-PRP-T combined vaccine in the Russian Federation and Poland.
    Medical condition: Prevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus type 1, 2 and 3, prevention against invasive infections caused by Haemophilus in...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10042613 - Surgical and medical procedures 10036897 Prophylactic vaccination LLT
    18.0 10042613 - Surgical and medical procedures 10043413 Therapeutic procedures and supportive care NEC HLGT
    18.0 10042613 - Surgical and medical procedures 10021430 Immunisation PT
    18.0 10042613 - Surgical and medical procedures 10021431 Immunisations HLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-007096-32 Sponsor Protocol Number: PREV1234 Start Date*: 2009-01-07
    Sponsor Name:Medizinische Universität Wien, Univ. Kinderklinik
    Full Title: Prevention od new sensitization by sublingual immunotherapy in children 2-4 years of age with allergic mono-sensitization
    Medical condition: Children (2-4years of age) from atopy prone families with an allergic sensitization as defined by positive skin prick test or positive allergen-specific IgE to grass pollen or house dust mite aller...
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001079-35 Sponsor Protocol Number: PRPK Start Date*: 2019-08-29
    Sponsor Name:Cliniques universitaires Saint-Luc
    Full Title: A prospective randomized study in ambulatory patients undergoing upper limb bone surgery under single shot axillary plexus block.
    Medical condition: Do patients who are very painful when the axillary block wears off after bone surgery of the upper limb have a pre-existing central sensitization? Could this “rebound pain” be prevented by pre-inc...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003067-31 Sponsor Protocol Number: 600-PG-PSC-156 Start Date*: 2006-09-25
    Sponsor Name:LETI Pharma GmbH
    Full Title: A randomized, double blinded, placebo controlled multicenter study for the efficacy and safety of Depigoid® tree pollen
    Medical condition: Rhinitis and/or rhinoconjunctivitis with or without allergic asthma caused by clinical relevant sensitization against tree pollen.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039083 Rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002844-18 Sponsor Protocol Number: 04071962 Start Date*: 2017-01-16
    Sponsor Name:Medical University of Vienna, Dpt. of Pediatrics
    Full Title: Preventive sublingual immunotherapy for house dust mite sensitized preschool children
    Medical condition: Patients; children at age 4 years with house dust mite IgE sensitization without allergic disease
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004433-14 Sponsor Protocol Number: A3L15 Start Date*: 2012-04-10
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Randomized, open, controlled, multicenter, Phase III trial in infants who will receive DTaP-IPV-Hep B-PRP-T (Group 1, N=286), CombAct-Hib™ and Engerix B™ Pediatric with OPV (Group 2, N=286), or DTa...
    Medical condition: Prevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus types 1, 2 and 3, prevention against invasive infections caused by Haemophilus i...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10021430 Immunisation PT
    14.1 10042613 - Surgical and medical procedures 10036897 Prophylactic vaccination LLT
    14.1 10042613 - Surgical and medical procedures 10021431 Immunisations HLT
    14.1 10042613 - Surgical and medical procedures 10043413 Therapeutic procedures and supportive care NEC HLGT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-004456-19 Sponsor Protocol Number: A3L21 Start Date*: 2012-04-10
    Sponsor Name:Sanofi Pasteur S.A
    Full Title: Phase III, open-label, multi-center booster vaccination study in toddlers who completed a three-dose primary series of the DTaP-IPV-Hep B-PRP-T combined vaccine or Infanrix hexa™ in Study A3L11.
    Medical condition: Prevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus types 1, 2 and 3, prevention against invasive infections caused by Haemophilus i...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10021430 Immunisation PT
    14.1 10042613 - Surgical and medical procedures 10036897 Prophylactic vaccination LLT
    14.1 10042613 - Surgical and medical procedures 10021431 Immunisations HLT
    14.1 10042613 - Surgical and medical procedures 10043413 Therapeutic procedures and supportive care NEC HLGT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-004457-87 Sponsor Protocol Number: A3L12 Start Date*: 2012-04-10
    Sponsor Name:Sanofi Pasteur S.A
    Full Title: A Phase III, randomized, blind-observer, controlled, multicenter trial in 412 infants in Thailand.
    Medical condition: Prevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus types 1, 2 and 3, prevention against invasive infections caused by Haemophilus i...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10021430 Immunisation PT
    14.1 10042613 - Surgical and medical procedures 10036897 Prophylactic vaccination LLT
    14.1 10042613 - Surgical and medical procedures 10021431 Immunisations HLT
    14.1 10042613 - Surgical and medical procedures 10043413 Therapeutic procedures and supportive care NEC HLGT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-005352-10 Sponsor Protocol Number: E2I34 Start Date*: 2015-12-04
    Sponsor Name:SANOFI PASTEUR INTERNATIONAL
    Full Title: Immunogenicity and Safety of the Aventis Pasteur DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM™) Given as a Three-Dose Primary Vaccination at 2, 4 and 6 Months of Age and Followed by a Booster Dose a...
    Medical condition: Healty volunteers: active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive infections caused by Haemophilus influenzae type b (such as meningitis, septicaemia, cellul...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10042613 - Surgical and medical procedures 10036897 Prophylactic vaccination LLT
    18.1 10042613 - Surgical and medical procedures 10043413 Therapeutic procedures and supportive care NEC HLGT
    18.1 10042613 - Surgical and medical procedures 10021430 Immunisation PT
    18.1 10042613 - Surgical and medical procedures 10021431 Immunisations HLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-004434-33 Sponsor Protocol Number: A3L17 Start Date*: 2012-04-10
    Sponsor Name:Sanofi Pasteur S.A
    Full Title: Phase III, randomized, blind-observer, single-center, controlled trial of the DTaP-IPV-Hep B-PRP-T vaccine in 266 healthy Peruvian infants.
    Medical condition: Prevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus types 1, 2 and 3, prevention against invasive infections caused by Haemophilus i...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10021430 Immunisation PT
    14.1 10042613 - Surgical and medical procedures 10036897 Prophylactic vaccination LLT
    14.1 10042613 - Surgical and medical procedures 10021431 Immunisations HLT
    14.1 10042613 - Surgical and medical procedures 10043413 Therapeutic procedures and supportive care NEC HLGT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-004454-26 Sponsor Protocol Number: A3L10 Start Date*: 2012-04-10
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Mono-center, open-label, randomized, active-controlled trial in 310 infants
    Medical condition: Prevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus types 1, 2 and 3, prevention against invasive infections caused by Haemophilus i...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10021430 Immunisation PT
    14.1 10042613 - Surgical and medical procedures 10036897 Prophylactic vaccination LLT
    14.1 10042613 - Surgical and medical procedures 10021431 Immunisations HLT
    14.1 10042613 - Surgical and medical procedures 10043413 Therapeutic procedures and supportive care NEC HLGT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-004428-36 Sponsor Protocol Number: A3L27 Start Date*: 2012-04-10
    Sponsor Name:Sanofi Pasteur S.A
    Full Title: Phase III, A3L24 extension protocol, randomized, blind-observer, multi-center booster vaccination study in toddlers who completed a three-dose primary series of DTaP-IPV-Hep B-PRP-T combined vaccin...
    Medical condition: Prevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus types 1, 2 and 3, prevention against invasive infections caused by Haemophilus i...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10021430 Immunisation PT
    14.1 10042613 - Surgical and medical procedures 10036897 Prophylactic vaccination LLT
    14.1 10042613 - Surgical and medical procedures 10021431 Immunisations HLT
    14.1 10042613 - Surgical and medical procedures 10043413 Therapeutic procedures and supportive care NEC HLGT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 18:51:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA